Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2026
Association between Statin Use and the Risk of Colorectal, Liver, and Lung Cancers: A Population-Based Retrospective Cohort Study.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Yau Sarah Tsz Yui, Hung Chi Tim, Leung Eman Yee Man, Lee Albert, Yeoh Eng Kiong
Аннотация
BACKGROUND: Epidemiologic studies on statin use and cancer risk demonstrated mixed findings. This study aims to (i) examine the associations between statin use and the risk of site-specific cancer (colorectal, liver, and lung) incidence and (ii) explore the role of statin use in the presence of other risk factors.
METHODS: A retrospective cohort study was conducted based on territory-wide electronic health records of Hong Kong between the years 2000 and 2021. Patients who had a complete lipid profile and no cancer history were identified. The associations between statin use and site-specific cancer incidence were examined using Cox regression. Subgroup analyses were performed by smoking or diabetes status. The interaction patterns between statin use and other risk factors were explored using survival tree analysis.
RESULTS: Of the 1,510,263 patients included, 753,504 and 756,759 were statin users and statin nonusers, respectively. Statin users seemed to have a lower risk of three cancers, with the strongest reduction in liver cancer [adjusted hazard ratio (aHR), 0.43; 95% confidence interval (CI), 0.40-0.45], followed by lung (aHR, 0.73; 95% CI, 0.71-0.76) and colorectal (aHR, 0.82; 95% CI, 0.79-0.85) cancers, when compared with nonusers. In subgroup analyses, the risk reduction was greater in diabetes but similar across smokers and nonsmokers. Statin use demonstrated an interaction pattern with smoking across three cancers and additionally with diabetes in liver cancer.
CONCLUSIONS: Statin use was associated with a lower risk of several common cancers, particularly in diabetes. Statin use, diabetes, and smoking may collectively exert differential influences on different cancer risks.
IMPACT: Statin use may confer additional protection against several site-specific cancers.
METHODS: A retrospective cohort study was conducted based on territory-wide electronic health records of Hong Kong between the years 2000 and 2021. Patients who had a complete lipid profile and no cancer history were identified. The associations between statin use and site-specific cancer incidence were examined using Cox regression. Subgroup analyses were performed by smoking or diabetes status. The interaction patterns between statin use and other risk factors were explored using survival tree analysis.
RESULTS: Of the 1,510,263 patients included, 753,504 and 756,759 were statin users and statin nonusers, respectively. Statin users seemed to have a lower risk of three cancers, with the strongest reduction in liver cancer [adjusted hazard ratio (aHR), 0.43; 95% confidence interval (CI), 0.40-0.45], followed by lung (aHR, 0.73; 95% CI, 0.71-0.76) and colorectal (aHR, 0.82; 95% CI, 0.79-0.85) cancers, when compared with nonusers. In subgroup analyses, the risk reduction was greater in diabetes but similar across smokers and nonsmokers. Statin use demonstrated an interaction pattern with smoking across three cancers and additionally with diabetes in liver cancer.
CONCLUSIONS: Statin use was associated with a lower risk of several common cancers, particularly in diabetes. Statin use, diabetes, and smoking may collectively exert differential influences on different cancer risks.
IMPACT: Statin use may confer additional protection against several site-specific cancers.